Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -154.73% is 88% above its 5-year average of -1325.91%, near the high end of its 5-year range (-25404.55%–570.96%).
98.46% above its 12-month average of -10024.57%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -25404.55%.
OPERATING MARGIN
-154.73%
OPERATING MARGIN AVG TTM
-10024.57%
OPERATING MARGIN AVG 3Y
-2655.98%
OPERATING MARGIN AVG 5Y
-1325.91%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+98.46%
CURRENT VS 3Y AVG
+94.17%
CURRENT VS 5Y AVG
+88.33%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 769 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Orchestra BioMed Holdings, Inc.
Market Cap
$351.20M
Operating Margin
-154.73%
TTM Avg
-10024.57%
3Y Avg
-2655.98%
5Y Avg
-1325.91%
Market Cap
$352.79M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$354.14M
Operating Margin
0.00%
TTM Avg
-13402.79%
3Y Avg
-7027.62%
5Y Avg
-5128.57%
Market Cap
$354.76M
Operating Margin
-14.22%
TTM Avg
-4.51%
3Y Avg
-387.94%
5Y Avg
-2012.06%
Market Cap
$357.66M
Operating Margin
-1425.70%
TTM Avg
-1388.03%
3Y Avg
-1860.44%
5Y Avg
-9490.29%
Market Cap
$358.19M
Operating Margin
-130.65%
TTM Avg
-155.28%
3Y Avg
-156.88%
5Y Avg
-129.07%
Market Cap
$359.96M
Operating Margin
24.85%
TTM Avg
23.00%
3Y Avg
24.99%
5Y Avg
31.17%
Market Cap
$362.88M
Operating Margin
-271.90%
TTM Avg
-418.31%
3Y Avg
-211.58%
5Y Avg
-783.53%
Market Cap
$330.11M
Operating Margin
-18.00%
TTM Avg
-67.22%
3Y Avg
-104.89%
5Y Avg
-90.63%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | $351.20M | -154.73% | -10024.57% | -2655.98% | -1325.91% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $352.79M | 0.00% | 0.00% | 0.00% | 0.00% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $354.14M | 0.00% | -13402.79% | -7027.62% | -5128.57% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $354.76M | -14.22% | -4.51% | -387.94% | -2012.06% |
| Ocugen, Inc. (OCGN)vs › | $357.66M | -1425.70% | -1388.03% | -1860.44% | -9490.29% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $358.19M | -130.65% | -155.28% | -156.88% | -129.07% |
| Embecta Corp. (EMBC)vs › | $359.96M | 24.85% | 23.00% | 24.99% | 31.17% |
| Opus Genetics, Inc. (IRD)vs › | $362.88M | -271.90% | -418.31% | -211.58% | -783.53% |
| Agenus Inc. (AGEN)vs › | $330.11M | -18.00% | -67.22% | -104.89% | -90.63% |
| Canopy Growth Corporation (CGC)vs › | $374.20M | -31.98% | -34.62% | -233.89% | -229.53% |
Gross Margin
99.3%
Operating Margin
-154.7%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -25404.55% |
| 2026-03-31 | -20069.09% |
| 2025-12-31 | 21.85% |
| 2025-09-30 | -2359.23% |
| 2025-06-30 | -2311.84% |
| 2025-03-31 | -2179.84% |
| 2024-12-31 | -6591.70% |
| 2024-09-30 | -1655.72% |
| 2024-06-30 | -2166.97% |
| 2024-03-31 | -2326.29% |
| 2023-12-31 | -4763.74% |
| 2023-09-30 | -3466.35% |
| 2023-06-30 | -1415.96% |
| 2023-03-31 | -991.84% |
| 2022-12-31 | -891.02% |
| 2022-09-30 | -865.61% |
| 2022-06-30 | -1903.74% |
| 2022-03-31 | -592.15% |
| 2021-12-31 | 322.34% |
| 2021-09-30 | -329.11% |
| 2021-06-30 | 570.96% |
| 2021-03-31 | -297.95% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
